Search
Grail Inc
GRALAdd to Watchlist
65.555USD
-1.015-1.52%
Market hours （ET）Quotes delayed by 15 min
2.70BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-25The current earnings forecast score of Grail Inc is 7.50, ranking 286 out of 387 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 110.00 and a low of 100.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
64.266
Target Price
-3.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Grail Inc
GRAL
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Grail Inc's expected revenue for the next quarter?
Grail Inc's expected revenue is 42.77M.
What is Grail Inc's price target?
Analysts forecast that Grail Inc's price target is USD 105.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 100.00.
How have Grail IncGRAL's recent earnings per share performed?
The market expectation was USD -2.29, while Grail IncGRAL's earnings per share (EPS) for the previous quarter was USD -2.43. EPS for the next quarter is expected at USD -2.65.
What is the analyst rating for Grail Inc?
Based on the ratings of Grail Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
